Patient associations argue “If Xalkori is introduced in the National Health Insurance Committee…”

The Pfizer’s non-small cell lung cancer treatment ‘Xalkori (generic name: crizotinib)’ has gotten closer to application of the National Health Insurance Service. It is expected that the benefit will be provided if the beneficiary case is decided at the National Health Insurance Evaluation Committee at the end of the month at soonest.

Pfizer Korea and the Health Insurance Corporation has made a...